Clinical
Weight Loss Trials of Diet Pills
Diet Pills Trials - Orlistat and Drug
Treatment of Obesity
Orlistat
(Xenical™, Hoffmann-La Roche) is a powerful inhibitor of gastrointestinal
lipase and as such, reduces fat absorption. Unlike other weight-reducing
drugs it is minimally absorbed and has no effects in the CNS. Orlistat
is indicated for patients with a body mass index (BMI) of at least 30
kg/m2 or 28 kg/m2 in the presence of obesity-associated complications,
such as hypertension, diabetes mellitus, hyperlipidaemia and obstructive
sleep apnoea.
In clinical weight loss trials, orlistat
(120 mg t.i.d.) in combination with life-style modification and a hypocaloric
diet (30 percent of energy from fat) induced significantly more weight
loss and improved health complications of obesity (diabetes, hypertension,
hyperlipidaemia) compared to patients treated with diet alone. Side effects
related to fat malabsorption, occurred in more than 20 percent of subjects
during the first year of treatment and included oily faecal spotting,
abdominal pain, flatus with discharge and fatty/oily stool. Side effects
from orlistat diminished in the second year of treatment.
Plasma concentrations of fat soluble vitamins
decreased in orlistat-treated patients but did not usually fall below
the normal range. No studies have evaluated the efficacy of orlistat or
side effect profile beyond two years.
Sources include: www.zerlina.ashley-pub.com
2002
Some Clinical Weight Loss Trials of Diet
Pills
Xenical
Diet Pills and Diabesity
Laxatives & Diet Pills
CLA Dietary Pills Trial
Orlistat Diet Pills Trial
Xenical/ Meridia Diet Pills
Xenical/ Orlistat Diet
Pills Trial
Meridia Diet Pills
Meridia & Dexfenfluramine
Sibutramine Diet Pills:
Health Trial
Meridia Diet Pills: Energy
Trial
Sibutramine Diet
Pills: Drug Abuse Trial
Sibutramine Diet Pills Trial
Sibutramine Diet Drugs:
Energy Trial
Orlistat/ Sibutramine
Diet Pills Trial
Orlistat/ Xenical Diet
Pills Trial
Dietary Supplements:
Weight Loss Trial
---------------------------------------------------------------------
|